The blood and vascular cell compatibility of heparin-modified ePTFE vascular grafts

Biomaterials

Volumn 34, Issue 1, 2013, Pages 30-41

  Hoshi, Ryan A ^a   Van Lith, Robert ^a   Jen, Michele C ^a   Allen, Josephine B ^b   Lapidos, Karen A ^a   Ameer, Guillermo ^a,c  

^a Northwestern University   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aminated poly(1,8 octanediol co citrate) (POC); Elastomer; Endothelial cell; Hemocompatibility; Heparin; Progenitor cell; Smooth muscle cell; Vascular graft

Indexed keywords

AMINATED POLY(1,8-OCTANEDIOL-CO-CITRATE) (POC); HEMOCOMPATIBILITY; HEPARIN; PROGENITOR CELL; SMOOTH MUSCLE CELLS; VASCULAR GRAFTS;

ADHESION; BLOOD VESSELS; CELL PROLIFERATION; DISEASES; ELASTOMERS; ENDOTHELIAL CELLS; FUNCTIONAL GROUPS; GLYCOPROTEINS; GRAFTS; PROTEINS;

POLYSACCHARIDES;

ALPHA ACTIN; CADHERIN; CARBOXYL GROUP; CITRIC ACID; HEPARIN; NITRIC OXIDE; POLY(1,8 OCTANEDIOL CO CITRATE); POLYESTER; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; BLOOD VESSEL GRAFT; CELL CULTURE; CELL INTERACTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; THROMBOCYTE ADHESION; THROMBOGENICITY;

ADULT; BIOCOMPATIBLE MATERIALS; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CITRATES; COATED MATERIALS, BIOCOMPATIBLE; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATERIALS TESTING; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; PHENOTYPE; PHOTOELECTRON SPECTROSCOPY; PLATELET ADHESIVENESS; POLYMERS; POLYTETRAFLUOROETHYLENE; THROMBOSIS;

EID: 84868115647     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.046     Document Type: Article

References (67)

1. Curi M.A., Skelly C.L., Meyerson S.L., Woo D.H., Desai T.R., McKinsey J.F., et al. Conduit choice for above-knee femoropopliteal bypass grafting in patients with limb-threatening ischemia. Ann Vasc Surg 2002, 16(1):95-101.
2. Albers M., Battistella V.M., Romiti M., Rodrigues A.A., Pereira C.A. Meta-analysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries. J Vasc Surg 2003, 37(6):1263-1269.
3. Lord M.S., Yu W., Cheng B., Simmons A., Poole-Warren L., Whitelock J.M. The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan. Biomaterials 2009, 30(28):4898-4906.
4. Wissink M.J., Beernink R., Pieper J.S., Poot A.A., Engbers G.H., Beugeling T., et al. Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization and in vitro evaluation. Biomaterials 2001, 22(2):151-163.
5. Chandy T., Das G.S., Wilson R.F., Rao G.H. Use of plasma glow for surface-engineering biomolecules to enhance blood compatibility of Dacron and PTFE vascular prosthesis. Biomaterials 2000, 21(7):699-712.
6. Zhou Z., Meyerhoff M.E. Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin. Biomaterials 2005, 26(33):6506-6517.
7. Larm O., Larsson R., Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983, 11(2-3):161-173.
8. Liu L., Guo S., Chang J., Ning C., Dong C., Yan D. Surface modification of polycaprolactone membrane via layer-by-layer deposition for promoting blood compatibility. J Biomed Mater Res B Appl Biomater 2008, 87(1):244-250.
9. Tseng P.Y., Rele S.S., Sun X.L., Chaikof E.L. Membrane-mimetic films containing thrombomodulin and heparin inhibit tissue factor-induced thrombin generation in a flow model. Biomaterials 2006, 27(12):2637-2650.
10. Sakariassen K.S., Joss R., Muggli R., Kuhn H., Tschopp T.B., Sage H., et al. Collagen type III induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990, 10(2):276-284.
11. Luong-Van E., Grøndahl L., Chua K.N., Leong K.W., Nurcombe V., Cool S.M. Controlled release of heparin from poly(e{open}-caprolactone) electrospun fibers. Biomaterials 2006, 27(9):2042-2050.
12. Allen J., Khan S., Serrano M.C., Ameer G. Characterization of porcine circulating progenitor cells: toward a functional endothelium. Tissue Eng Part A 2008, 14(1):183-194.
13. Allen J.B., Khan S., Lapidos K.A., Ameer G.A. Toward engineering a human neoendothelium with circulating progenitor cells. Stem Cells 2010, 28(2):318-328.
14. Hoshi R.A., Behl S., Ameer G.A. Nanoporous biodegradable elastomers. Adv Mater 2009, 21(2):188-192.
15. Motlagh D., Allen J., Hoshi R., Yang J., Lui K., Ameer G. Hemocompatibility evaluation of poly(diol citrate) in vitro for vascular tissue engineering. J Biomed Mater Res A 2007, 82(4):907-916.
16. Yang J., Motlagh D., Allen J.B., Webb A.R., Kibbe M.R., Aalami O., et al. Modulating expanded polytetrafluoroethylene vascular graft host response via citric acid-based biodegradable elastomers. Adv Mater 2006, 18(12):1493-1498.
17. Yang J., Motlagh D., Webb A.R., Ameer G.A. Novel biphasic elastomeric scaffold for small-diameter blood vessel tissue engineering. Tissue Eng 2005, 11(11-12):1876-1886.
18. Yang J., Webb A.R., Ameer G.A. Novel citric acid-based biodegradable elastomers for tissue engineering. Adv Mater 2004, 16(6):511-516.
19. Yang J., Webb A.R., Pickerill S.J., Hageman G., Ameer G.A. Synthesis and evaluation of poly(diol citrate) biodegradable elastomers. Biomaterials 2006, 27(9):1889-1898.
20. Chung E.J., Sugimoto M.J., Ameer G.A. The role of hydroxyapatite in citric acid-based nanocomposites: surface characteristics, degradation, and osteogenicity in vitro. Acta Biomater 2011, 7(11):4057-4063.
21. Webb A.R., Kumar V.A., Ameer G.A. Biodegradable poly(diol citrate) nanocomposite elastomers for soft tissue engineering. J Mater Chem 2007, 17(9):900-906.
22. Sharma A.K., Hota P.V., Matoka D.J., Fuller N.J., Jandali D., Thaker H., et al. Urinary bladder smooth muscle regeneration utilizing bone marrow derived mesenchymal stem cell seeded elastomeric poly(1,8-octanediol-co-citrate) based thin films. Biomaterials 2010, 31(24):6207-6217.
23. Asahara T., Kawamoto A., Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011, 29(11):1650-1655.
24. Ueda M., Alferiev I.S., Simons S.B., Hebbel R.P., Levy R.J., Stachelek S.J. CD47-dependent molecular mechanisms of blood outgrowth endothelial cell attachment on cholesterol-modified polyurethane. Biomaterials 2010, 31(25):6394-6399.
25. Zhu C., Ying D., Mi J., Li L., Zeng W., Hou C., et al. Development of anti-atherosclerotic tissue-engineered blood vessel by A20-regulated endothelial progenitor cells seeding decellularized vascular matrix. Biomaterials 2008, 29(17):2628-2636.
26. Jantzen A.E., Lane W.O., Gage S.M., Jamiolkowski R.M., Haseltine J.M., Galinat L.J., et al. Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model. Biomaterials 2011, 32(33):8356-8363.
27. Gupta B., Plummer C., Bisson I., Frey P., Hilborn J. Plasma-induced graft polymerization of acrylic acid onto poly(ethylene terephthalate) films: characterization and human smooth muscle cell growth on grafted films. Biomaterials 2002, 23(3):863-871.
28. Smith P.K., Mallia A.K., Hermanson G.T. Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal Biochem 1980, 109(2):466-473.
29. Weber N., Wendel H.P., Ziemer G. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002, 23(2):429-439.
30. Grunkemeier J.M., Tsai W.B., Horbett T.A. Hemocompatibility of treated polystyrene substrates: contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J Biomed Mater Res 1998, 41(4):657-670.
31. Kojima H., Nakatsubo N., Kikuchi K., Kawahara S., Kirino Y., Nagoshi H., et al. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem 1998, 70(13):2446-2453.
32. Eppley B.L., Pietrzak W.S., Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg 2006, 118(6):147e-159e.
33. Yang Z., Wang J., Luo R., Maitz M.F., Jing F., Sun H., et al. The covalent immobilization of heparin to pulsed-plasma polymeric allylamine films on 316L stainless steel and the resulting effects on hemocompatibility. Biomaterials 2010, 31(8):2072-2083.
34. Frojmovic M.M., Milton J.G. Human platelet size, shape, and related functions in health and disease. Physiol Rev 1982, 62(1):185-261.
35. Deutsch M., Meinhart J., Zilla P., Howanietz N., Gorlitzer M., Froeschl A., et al. Long-term experience in autologous in vitro endothelialization of infrainguinal ePTFE grafts. J Vasc Surg 2009, 49(2):352-362.
36. Kirkwood M.L., Wang G.J., Jackson B.M., Golden M.A., Fairman R.M., Woo E.Y. Lower limb revascularization for PAD using a heparin-coated PTFE conduit. Vasc Endovascular Surg 2011, 45(4):329-334.
37. Heyligers J.M., Lisman T., Verhagen H.J., Weeterings C., de Groot P.G., Moll F.L. A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. J Vasc Surg 2008, 47(2):324-329. discussion 9.
38. Tatterton M., Wilshaw S.P., Ingham E., Homer-Vanniasinkam S. The use of antithrombotic therapies in reducing synthetic small-diameter vascular graft thrombosis. Vasc Endovascular Surg 2012, 46(3):212-222.
39. Kapadia M.R., Popowich D.A., Kibbe M.R. Modified prosthetic vascular conduits. Circulation 2008, 117(14):1873-1882.
40. Scharn D.M., Dirven M., Barendregt W.B., Boll A.P., Roelofs D., van der Vliet J.A. Human umbilical vein versus heparin-bonded polyester for femoro-popliteal bypass: 5-year results of a prospective randomized multicentre trial. Eur J Vasc Endovasc Surg 2008, 35(1):61-67.
41. Devine C., McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg 2004, 40(5):924-931.
42. ® Trial - 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses - a randomised clinical controlled multi-centre trial. Eur J Vasc Endovasc Surg 2011, 41(5):668-673.
43. Bosiers M., Deloose K., Verbist J., Schroe H., Lauwers G., Lansink W., et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J Vasc Surg 2006, 43(2):313-318. discussion 8-9.
44. Lin P.H., Bush R.L., Yao Q., Lumsden A.B., Chen C. Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model. J Surg Res 2004, 118(1):45-52.
45. Brunot C., Ponsonnet L., Lagneau C., Farge P., Picart C., Grosgogeat B. Cytotoxicity of polyethyleneimine (PEI), precursor base layer of polyelectrolyte multilayer films. Biomaterials 2007, 28(4):632-640.
46. Arepally G.M., Ortel T.L. Heparin-induced thrombocytopenia. N Engl J Med 2006, 355(8):809-817.
47. Alferiev I.S., Connolly J.M., Stachelek S.J., Ottey A., Rauova L., Levy R.J. Surface heparinization of polyurethane via bromoalkylation of hard segment nitrogens. Biomacromolecules 2005, 7(1):317-322.
48. Bae J.-S., Seo E.-J., Kang I.-K. Synthesis and characterization of heparinized polyurethanes using plasma glow discharge. Biomaterials 1999, 20(6):529-537.
49. Chuang T.-W., Masters K.S. Regulation of polyurethane hemocompatibility and endothelialization by tethered hyaluronic acid oligosaccharides. Biomaterials 2009, 30(29):5341-5351.
50. Michanetzis G.P., Katsala N., Missirlis Y.F. Comparison of haemocompatibility improvement of four polymeric biomaterials by two heparinization techniques. Biomaterials 2003, 24(4):677-688.
51. Lindhout T., Blezer R., Schoen P., Willems G.M., Fouache B., Verhoeven M., et al. Antithrombin activity of surface-bound heparin studied under flow conditions. J Biomed Mater Res 1995, 29(10):1255-1266.
52. Li G., Yang P., Qin W., Maitz M.F., Zhou S., Huang N. The effect of coimmobilizing heparin and fibronectin on titanium on hemocompatibility and endothelialization. Biomaterials 2011, 32(21):4691-4703.
53. Sanchez J., Elgue G., Riesenfeld J., Olsson P. Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence. J Biomed Mater Res 1995, 29(5):655-661.
54. Pankowsky D.A., Ziats N.P., Topham N.S., Ratnoff O.D., Anderson J.M. Morphologic characteristics of adsorbed human plasma proteins on vascular grafts and biomaterials. J Vasc Surg 1990, 11(4):599-606.
55. Barbucci R., Magnani A. Conformation of human plasma proteins at polymer surfaces: the effectiveness of surface heparinization. Biomaterials 1994, 15(12):955-962.
56. Xiao Z., Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97(3):251-256.
57. Wang Y.-X., Robertson J.L., Spillman W.B., Claus R.O. Effects of the chemical structure and the surface properties of polymeric biomaterials on their biocompatibility. Pharm Res 2004, 21(8):1362-1373.
58. Clowes A.W., Reidy M.A., Clowes M.M. Mechanisms of stenosis after arterial injury. Lab Invest 1983, 49(2):208-215.
59. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84(3):767-801.
60. Peyton S.R., Raub C.B., Keschrumrus V.P., Putnam A.J. The use of poly(ethylene glycol) hydrogels to investigate the impact of ECM chemistry and mechanics on smooth muscle cells. Biomaterials 2006, 27(28):4881-4893.
61. Letourneur D., Caleb B.L., Castellot J.J. Heparin binding, internalization, and metabolism in vascular smooth muscle cells: I. Upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol 1995, 165(3):676-686.
62. McGuigan A.P., Sefton M.V. The influence of biomaterials on endothelial cell thrombogenicity. Biomaterials 2007, 28(16):2547-2571.
63. He H., Shirota T., Yasui H., Matsuda T. Canine endothelial progenitor cell-lined hybrid vascular graft with nonthrombogenic potential. J Thorac Cardiovasc Surg 2003, 126(2):455-464.
64. Schmidt D., Asmis L.M., Odermatt B., Kelm J., Breymann C., Gössi M., et al. Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. Ann Thorac Surg 2006, 82(4):1465-1471.
65. Griese D.P., Ehsan A., Melo L.G., Kong D., Zhang L., Mann M.J., et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts. Circulation 2003, 108(21):2710-2715.
66. Janairo R.R., Henry J.J., Lee B.L., Hashi C.K., Derugin N., Lee R., et al. Heparin-modified small-diameter nanofibrous vascular grafts. IEEE Trans Nanobioscience 2012, 11(1):22-27.
67. Begovac P.C., Thomson R.C., Fisher J.L., Hughson A., Gallhagen A. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg 2003, 25(5):432-437.